The Utah-based company has a diverse pipeline of products, including TP-0413 for chronic inflammatory diseases, TP-0829 for B-cell lymphomas and leukemia, TP-0903 for pancreatic cancer, TP-0227 for endometrial carcinomas, and TP-1149 for myeloma. Tolero Pharmaceuticals also has a strategic partnership with MannKind Corporation. Their focus is on targeting important biological drivers of blood disorders to treat leukemias and anemia, as well as drug resistance and transcriptional control.